Floatz logo

Letermovir

Hematopoietic and Lymphoid Cell Neoplasm

Children's Oncology GroupSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB

View all 50 →

Same molecule, other indications

Letermovir is also rated in:

chronic myeloid leukemiaDormant
B
Indicative ·
58 / 100
View asset →
myeloproliferative neoplasmDormant
B
Indicative ·
58 / 100
View asset →
disease related to transplantationDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →